By Gilang Cahya 
Genetically tailored treatment plans for children with a type of kidney cancer could help provide the most effective care while minimising side effects as much as possible.
A groundbreaking study, published on January 23rd in the esteemed journal Cancer Discovery, has unveiled critical genetic insights into Wilms tumour, a prevalent form of childhood kidney cancer. Researchers from leading institutions including the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust, Great Ormond Street Hospital, and the University of Würzburg, alongside their international collaborators, have meticulously mapped the genetic landscape of Wilms tumour in affected children. This extensive research promises to usher in an era of precision medicine, enabling highly personalized treatment strategies that could significantly improve outcomes and reduce the long-term health burdens for young patients.
Unraveling the Genetic Roots of Wilms Tumour
Wilms tumour, primarily diagnosed in children under the age of five, affects approximately 85 children annually in the UK. While the majority of cases arise from spontaneous genetic mutations occurring during fetal development, a significant subset, around 30 percent, is linked to inherited genetic predispositions. These inherited changes not only elevate the risk of developing the cancer but, as this new study demonstrates, profoundly influence its developmental trajectory, its responsiveness to therapy, and the patient’s susceptibility to secondary cancers later in life.
The research team’s comprehensive genetic analysis of hundreds of tissue samples from 137 children with Wilms tumour has illuminated a crucial dichotomy in tumour development. Their findings reveal that Wilms tumours develop through distinct pathways depending on whether an inherited genetic predisposition is present. In children with such predispositions, the study indicates that specific inherited genetic changes predetermine the nature of tumour growth, dictating how the tumour will respond to various treatments and influencing the individual’s risk of developing other cancers in the future. Conversely, tumours in children without these genetic predispositions follow a different developmental course.
Tailoring Therapies to Individual Genetic Blueprints
The implications of these findings are far-reaching, suggesting a paradigm shift in how Wilms tumour is managed. Currently, treatment for children with a known genetic predisposition involves a delicate balancing act: aggressively removing the tumour to mitigate the risk of secondary cancers while simultaneously striving to preserve as much healthy kidney function as possible. This often necessitates a combination of chemotherapy, specific surgical techniques, and extended post-operative chemotherapy, coupled with vigilant surveillance for recurrence.
However, the new research proposes a more nuanced approach. By understanding the specific genetic underpinnings of an individual child’s tumour, clinicians may be able to refine treatment protocols. For instance, identifying specific genetic predispositions that inherently restrict tumour growth could lead to less aggressive surgical interventions, thereby preserving more kidney tissue and minimizing long-term complications. Conversely, genetic profiles indicating a higher risk of aggressive tumour development or secondary cancers could inform more intensive treatment strategies from the outset.
Professor Sam Behjati, co-senior author of the study and a leading figure at the Wellcome Sanger Institute and Cambridge University Hospitals NHS Foundation Trust, emphasized the transformative potential of this research. "Our research illustrates the power of collaborative genomic research to answer important clinical questions," Professor Behjati stated. "At the moment, we treat all children with a predisposition the same, meaning that some children get too much and others too little treatment. Our findings indicate that we may be able to personalise treatment on the basis of genetic information."
A Deeper Understanding of Tumour Heterogeneity
The study meticulously detailed how different genetic predispositions contribute to distinct tumour development pathways and variations in kidney structures. Notably, the researchers identified specific genetic profiles that appear to naturally inhibit tumour growth. This level of granularity in understanding tumour biology, driven by genetic variations, was previously unattainable.
The investigation revealed that the developmental timing of gene activation during fetal development plays a critical role. For children with a genetic predisposition, the specific gene affected and the stage at which it was activated in the womb dictated the manner in which their tumours developed. This led to the identification of specific DNA changes, known as "driver mutations," that are responsible for tumour formation. Some of these driver mutations were also found to increase the risk of secondary cancers in addition to Wilms tumour.
Targeting Key Genetic Pathways for Future Therapies
A significant breakthrough from the study involves the identification of specific genes, namely WT1 and TRIM28, where genetic alterations can lead to the accumulation of additional driver mutations within particular cellular pathways. This discovery opens exciting avenues for the development of novel targeted therapies. By understanding these precise molecular mechanisms, future drug development efforts can focus on interfering with these specific pathways, potentially halting cancer formation at its earliest stages or preventing its progression.
Dr. Taryn Treger, co-first author of the study from the Wellcome Sanger Institute, highlighted the predictive power of their findings. "Certain genetic changes that children are born with can predispose to Wilms tumour," Dr. Treger explained. "What we show in our research is that cancers develop in different ways, depending on what the underlying genetic change is. This means that in some predispositions we can exactly predict what additional genetic changes lead to cancer development, paving the path to identify treatments that interfere with cancer formation in the first place."
Beyond Treatment: Enhanced Screening and Prevention Strategies
The impact of this research extends beyond therapeutic interventions to encompass enhanced screening and potentially even preventative measures. The study’s findings suggest that genetic predisposition not only influences tumour development but also affects the overall tissue architecture of the kidneys. This could offer explanations for why some children develop non-cancerous kidney growths prior to the onset of cancerous tumours.
By precisely identifying the genetic changes that lead from a predisposition to the development of cancer, researchers believe it may become possible to refine screening programmes. This could allow for more targeted and effective surveillance, potentially identifying tumours at an earlier and more treatable stage. Professor Behjati further elaborated on this prospect: "Moreover, since we now know the precise sequence of genetic changes that lead from predisposition to cancer, we may be able to screen for tumours more effectively and even begin to entertain the possibility of prevention."
A Collaborative Effort with Broad Support
The success of this ambitious research underscores the importance of interdisciplinary collaboration and the critical role of funding from organizations dedicated to advancing childhood cancer research. The Little Princess Trust, a charity that provides vital funding for research into childhood cancers and supports families affected by the disease, was a key supporter of this study.
Phil Brace, Chief Executive of The Little Princess Trust, expressed optimism about the study’s potential to alleviate the burden of treatment on young patients. "Childhood cancer treatment can have substantial adverse effects that impact the child living with the condition, and those around them," Mr. Brace stated. "We believe that it is crucial to fund studies that not only look for ways to improve a young person’s chance of survival but also reduce the side effects from treatment. We are hopeful that this research may help tailor treatments in the future."
The Road Ahead: From Bench to Bedside
The journey from genetic discovery to clinical implementation is often a long one, but the findings of this study represent a significant leap forward. The detailed genetic mapping of Wilms tumour has provided an unprecedented understanding of the disease’s heterogeneity, laying the groundwork for a future where treatment decisions are guided by a child’s unique genetic profile.
The implications for patients are profound. By moving away from a one-size-fits-all approach, clinicians can aim to optimize treatment efficacy, minimize exposure to toxic therapies, and reduce the risk of long-term side effects, thereby improving the quality of life for survivors. The potential for more targeted drug development and refined screening strategies offers further hope for improved outcomes and a potential shift towards preventative approaches for those at the highest genetic risk. This research marks a pivotal moment in the fight against Wilms tumour, ushering in a new era of personalized, precision medicine for the youngest cancer patients.
